Landmark victory for individuals living with DEB and their families, the FDA announced their approval of Krystal Biotech's VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB).Business Wire • 05/19/23
Krystal Biotech stock rises after FDA approves treatment for rare skin diseaseMarket Watch • 05/19/23
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 05/19/23
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 05/08/23
Krystal Biotech: Harnessing Genetic Medicine To Transform Rare Disease TreatmentSeeking Alpha • 05/05/23
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use ProgramGlobeNewsWire • 04/24/23
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual MeetingGlobeNewsWire • 04/13/23
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care ConferenceGlobeNewsWire • 03/02/23
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational ProgressGlobeNewsWire • 02/27/23
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic FibrosisGlobeNewsWire • 01/18/23
Krystal Biotech Announces FDA's 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 01/09/23
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 12/14/22
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic ConferenceGlobeNewsWire • 12/05/22
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap ConferenceGlobeNewsWire • 12/01/22